Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 244

1.

CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.

Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC Jr, Liu J.

Int J Gynecol Cancer. 2013 Jun;23(5):815-22. doi: 10.1097/IGC.0b013e31828f7a24.

2.

Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.

Gadducci A, Cosio S, Zola P, Sostegni B, Fuso L, Sartori E.

Int J Gynecol Cancer. 2013 Mar;23(3):461-8. doi: 10.1097/IGC.0b013e318286665b.

PMID:
23370604
3.
4.

Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival.

Pradjatmo H, Pradjatmo H.

Asian Pac J Cancer Prev. 2016;17(4):1881-6.

5.

IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients.

Chen YL, Chou CY, Chang MC, Lin HW, Huang CT, Hsieh SF, Chen CA, Cheng WF.

Endocr Relat Cancer. 2015 Oct;22(5):703-11. doi: 10.1530/ERC-15-0145. Epub 2015 Jul 6.

6.

"The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".

Pereira A, Pérez-Medina T, Magrina JF, Magtibay PM, Rodríguez-Tapia A, Cuesta-Guardiola T, Peregrin I, Mendizabal E, Lizarraga S, Ortiz-Quintana L.

Surg Oncol. 2016 Mar;25(1):49-59. doi: 10.1016/j.suronc.2015.12.005. Epub 2016 Feb 10.

PMID:
26979641
7.

Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.

Nassar HR, Zeeneldin AA, Helal AM, Ismail YM, Elsayed AM, Elbassuiony MA, Moneer MM.

Asian Pac J Cancer Prev. 2015;16(16):7237-42.

8.

A detailed study of patients and tumor characteristics of epithelial ovarian cancer in Saudi women.

Al-Badawi IA, Munkarah AR, Tulbah A, Babic II, Al Husaini H, Ahmad S.

Int J Gynecol Cancer. 2013 Mar;23(3):456-60. doi: 10.1097/IGC.0b013e318284aafe.

PMID:
23360812
9.

Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study.

Sabatier R, Calderon B Jr, Lambaudie E, Chereau E, Provansal M, Cappiello MA, Viens P, Rousseau F.

Int J Gynecol Cancer. 2015 Jun;25(5):815-22. doi: 10.1097/IGC.0000000000000418.

PMID:
25768081
10.

Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.

Panici PB, Marchetti C, Salerno L, Musella A, Vertechy L, Palaia I, Perniola G, Ruscito I, Boni T, Angioli R, Muzii L.

Ann Surg Oncol. 2014 Sep;21(9):3036-41. doi: 10.1245/s10434-014-3714-6. Epub 2014 Apr 28.

PMID:
24770721
11.

Treatment failure in endometrial carcinoma.

Huang HJ, Tang YH, Chou HH, Yang LY, Chao A, Huang YT, Lin G, Liu FY, Chang TC, Lai CH.

Int J Gynecol Cancer. 2014 Jun;24(5):885-93. doi: 10.1097/IGC.0000000000000131.

PMID:
24819657
12.

Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivity.

Shaboodien R, Diamantis N, Blagden S, Gabra H, Agarwal R.

Int J Gynecol Cancer. 2013 Mar;23(3):481-7. doi: 10.1097/IGC.0b013e31828702f6.

PMID:
23392404
13.

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.

Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ.

Lancet Oncol. 2013 Aug;14(9):853-62. doi: 10.1016/S1470-2045(13)70253-5. Epub 2013 Jul 9.

14.

HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up.

Geisler JP, Tammela JE, Manahan KJ, Geisler HE, Miller GA, Zhou Z, Wiemann MC.

Eur J Gynaecol Oncol. 2004;25(2):165-8.

PMID:
15032273
15.

Elevated growth differentiation factor 15 expression predicts poor prognosis in epithelial ovarian cancer patients.

Zhang Y, Hua W, Niu LC, Li SM, Wang YM, Shang L, Zhang C, Li WN, Wang R, Chen BL, Xin XY, Zhang YQ, Wang J.

Tumour Biol. 2016 Jul;37(7):9423-31. doi: 10.1007/s13277-015-4699-x. Epub 2016 Jan 18. Erratum in: Tumour Biol. 2016 Jun;37(6):8465.

PMID:
26781874
16.

Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.

Gasimli K, Braicu EI, Nassir M, Richter R, Babayeva A, Chekerov R, Darb-Esfahani S, Sehouli J, Muallem MZ.

Ann Surg Oncol. 2016 Apr;23(4):1279-86. doi: 10.1245/s10434-015-4959-4. Epub 2016 Jan 29.

PMID:
26832880
17.

Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.

Fotopoulou C, Zang R, Gultekin M, Cibula D, Ayhan A, Liu D, Richter R, Braicu I, Mahner S, Harter P, Trillsch F, Kumar S, Peiretti M, Dowdy SC, Maggioni A, Trope C, Sehouli J.

Ann Surg Oncol. 2013 Apr;20(4):1348-54. doi: 10.1245/s10434-012-2673-z. Epub 2012 Oct 2.

PMID:
23054114
18.

Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.

Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, Siddiqui N, Colombo N, Bookman MA, Pfisterer J, du Bois A; Gynecologic Cancer InterGroup.

Int J Gynecol Cancer. 2010 Aug;20(6):945-52. doi: 10.1111/IGC.0b013e3181dd0110. Review.

PMID:
20683400
19.

Impact of prognostic factors on survival rates in patients with ovarian carcinoma.

Arikan SK, Kasap B, Yetimalar H, Yildiz A, Sakarya DK, Tatar S.

Asian Pac J Cancer Prev. 2014;15(15):6087-94.

20.

Postrecurrent oncologic outcome of patients with ovarian clear cell carcinoma.

Kajiyama H, Shibata K, Mizuno M, Yamamoto E, Fujiwara S, Umezu T, Suzuki S, Nakanishi T, Nagasaka T, Kikkawa F.

Int J Gynecol Cancer. 2012 Jun;22(5):801-6. doi: 10.1097/IGC.0b013e3182540145.

PMID:
22617480

Supplemental Content

Support Center